By Doug Macron
Leonardo Biosystems said this week that it has received the second half of a $2.5 million grant from the Texas Emerging Technology Fund to help develop its multi-stage drug-delivery technology.
The first half of the grant was received in April 2010.
Arrowhead Research this week released a white paper detailing the dynamic polyconjugate siRNA-delivery technology it picked up through its recent acquisition of Roche's RNA therapeutics assets.
Access Pharmaceuticals this week announced that it has signed a deal under which its CobaCyte and CobOral siRNA delivery technologies will be evaluated by an undisclosed pharmaceutical company.
Marina Biotech this week announced that the incorporation of a proprietary technology into an siRNA could reduce toxicity caused by microRNA-like off-target activity.
Silence Therapeutics this week announced that it has signed a deal under which one of its proprietary siRNA delivery technologies will be evaluated by an undisclosed “global pharmaceutical” company.
By Ben Butkus
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.